Novartis’ Lung Cancer Drug Nabs FDA Priority Review

The FDA granted priority review to Novartis for capmatinib (INC280) as a treatment for first line and previously treated patients with locally advanced or metastatic MET exon 14 skipping (METex14) mutated non-small cell lung cancer.

The NDA was supported by results from a phase 2 clinical trial in which capmatinib showed an overall response rate of 67.9 percent for treatment-naïve patients and 40.6 percent among and previously treated patients.

If approved, capmatinib will be the first therapy to specifically target METex14 mutated advanced lung cancer.